You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

t(11,14) positive relapsed/refractory (R/R) multiple myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Belantamab mafodotin, Venetoclax
  • (no location specified)
May 10, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 17, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Multiple Myeloma Trial in Shenyang (IM21 CAR-T cells)

Recruiting
  • Multiple Myeloma
  • IM21 CAR-T cells
  • Shenyang, Liaoning, China
    Hospital of China Medical University
Jul 26, 2022

Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jun 22, 2023

Multiple Myeloma, Relapsed Hematologic Malignancy Trial in Seattle (Digital Health Coaching Program, Fitbit)

Recruiting
  • Multiple Myeloma
  • Relapsed Hematologic Malignancy
  • Digital Health Coaching Program
  • Fitbit
  • Seattle, Washington
    University of Washington
Jul 13, 2023

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Multiple Myeloma Trial in Worldwide (Cevostamab, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +17 more
Jan 23, 2023

Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)

Recruiting
  • Multiple Myeloma
  • Human BCMA Targeted T Cells Injection
  • Shanghai, Shanghai, China
  • +1 more
Dec 7, 2022

Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • GIC-102 (Allogeneic NK cells)
  • Gyeonggi-do, Korea, Republic of
  • +3 more
May 18, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • APRIL CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
May 3, 2022

Multiple Myeloma Trial in Shanghai (Human Derived anti-BCMA CAR-T Injection)

Recruiting
  • Multiple Myeloma
  • Human Derived anti-BCMA CAR-T Injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Mar 27, 2022

Multiple Myeloma Trial in Beijing (melphalan HCl for injection)

Recruiting
  • Multiple Myeloma
  • melphalan hydrochloride for injection
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 26, 2022

Selinexor in Relapsed or Refractory Multiple Myeloma - SEATTLE-

Recruiting
  • Multiple Myeloma
  • Wien, Austria
  • +1 more
Jul 13, 2023

Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

Recruiting
  • Hematologic Diseases
  • Neoplasms
  • CD7 CAR-T cells injection
  • Allogeneic hematopoietic stem cell transplantation
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023

Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma (RRMM)
  • Non-Interventional
  • (no location specified)
Dec 21, 2022

Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023

Multiple Myeloma Trial in Hangzhou (GPRC5D-CAR-T)

Recruiting
  • Multiple Myeloma
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 12, 2022

Refractory or Relapsed Multiple Myeloma Trial (LCAR-B38M CAR-T cell injection)

Unknown status
  • Refractory or Relapsed Multiple Myeloma
  • LCAR-B38M CAR-T cell injection
  • (no location specified)
Aug 31, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Phoenix, Arizona
    Mayo Clinic Hospital in Arizona
Jan 4, 2023

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Relapsed or Refractory Multiple Myeloma Trial in Beijing (Mitoxantrone Hydrochloride Liposome injection, Bortezomib for

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Mitoxantrone Hydrochloride Liposome injection
  • +2 more
  • Beijing, Beijing, China
    Beijing Chaoyang Hospital, Capital Medical University
Jan 16, 2022